Physician profile
Joel Bronstein
NPI 1912380718
$15,607.27
in general payments reported to CMS, 2019-2025
7 companies · $2,635 in 2025
The $2,635 reported for 2025 was more than what 88% of Plastic Surgery providers received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,683 · 2020: $20.90 · 2022: $226 · 2023: $3,575 · 2024: $4,468 · 2025: $2,635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,701 · Consulting Fee: $3,072 · Food and Beverage: $2,905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,700.74 |
| Consulting Fee | $3,072.00 |
| Food and Beverage | $2,905.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $9,805.74 | 2023-2025 | Natrelle Saline-Filled Breast Implants, Strattice Reconstructive Tissue Matrix Bps, Botox |
| Allergan, INC. | $3,518.48 | 2019-2022 | |
| Stryker Corporation | $1,617.04 | 2019-2024 | |
| Becton, Dickinson and Company | $380.00 | 2025 | |
| Integra Lifesciences Corporation | $146.02 | 2019 | |
| Zimmer Biomet Holdings, INC. | $119.09 | 2019 | |
| Kci USA, INC. | $20.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Bronstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.